These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29569472)

  • 21. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
    Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
    Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Regorafenib approved in Metastatic Colorectal cancer].
    André T; Dumont SN
    Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regorafenib for cancer.
    Strumberg D; Schultheis B
    Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.
    Xue WS; Men SY; Liu W; Liu RH
    Medicine (Baltimore); 2018 Oct; 97(40):e12635. PubMed ID: 30290640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
    Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
    Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.
    Sastre J; Argilés G; Benavides M; Feliú J; García-Alfonso P; García-Carbonero R; Grávalos C; Guillén-Ponce C; Martínez-Villacampa M; Pericay C
    Clin Transl Oncol; 2014 Nov; 16(11):942-53. PubMed ID: 25223744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
    Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
    Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
    Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
    Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
    García-Alfonso P; Feliú J; García-Carbonero R; Grávalos C; Guillén-Ponce C; Sastre J; García-Foncillas J
    Clin Transl Oncol; 2016 Nov; 18(11):1072-1081. PubMed ID: 27037815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 37. [Investigation of Administration Technique of Regorafenib in Our Center].
    Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Motoori M; Nakatsuka R; Nishimura M; Kitagawa A; Takagi M; Iwase K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):47-51. PubMed ID: 28174379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
    Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
    Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
    BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
    Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
    Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.